BR112018008330A2 - compostos 1,3,4-tiadiazol e seu uso no tratamento de câncer - Google Patents

compostos 1,3,4-tiadiazol e seu uso no tratamento de câncer

Info

Publication number
BR112018008330A2
BR112018008330A2 BR112018008330-5A BR112018008330A BR112018008330A2 BR 112018008330 A2 BR112018008330 A2 BR 112018008330A2 BR 112018008330 A BR112018008330 A BR 112018008330A BR 112018008330 A2 BR112018008330 A2 BR 112018008330A2
Authority
BR
Brazil
Prior art keywords
cancer treatment
thiadiazole compounds
compound
formula
taken together
Prior art date
Application number
BR112018008330-5A
Other languages
English (en)
Other versions
BR112018008330B1 (pt
Inventor
Raymond Verschoyle Finlay Maurice
Robert Perkins David
Wilhelmus Maria Nissink Johannes
Antoni Raubo Piotr
Duncan Smith Peter
Bailey Andrew
Original Assignee
Astrazeneca Ab
Cancer Research Technology Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Cancer Research Technology Limited filed Critical Astrazeneca Ab
Publication of BR112018008330A2 publication Critical patent/BR112018008330A2/pt
Publication of BR112018008330B1 publication Critical patent/BR112018008330B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

é descrito um composto de fórmula (i): (i) ou um sal farmaceuticamente aceitável do mesmo. q pode ser piridazin-3-ila, 6-fluoropiridazin-3-ila; r1 pode ser h; r2 e r3 podem ser, cada um independentemente, c1-c6 alquila ou r2 e r3, tomados em conjunto, são -(ch2)3-; ou r1 e r2, tomados em conjunto, podem ser -(ch2)2- e r3 pode ser -ch3; r4 halo, -ch3, -och3, -ochf2, -ocf3 ou -cn; e n pode ser 0, 1 ou 2. o composto de fórmula (i) pode inibir a glutaminase, por exemplo, gls1.
BR112018008330-5A 2015-11-30 2016-11-30 Compostos 1,3,4-tiadiazol, composição farmacêutica compreendendo o mesmo e seu uso no tratamento de câncer BR112018008330B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562260784P 2015-11-30 2015-11-30
US62/260,784 2015-11-30
PCT/EP2016/079253 WO2017093301A1 (en) 2015-11-30 2016-11-30 1,3,4-thiadiazole compounds and their use in treating cancer

Publications (2)

Publication Number Publication Date
BR112018008330A2 true BR112018008330A2 (pt) 2018-10-30
BR112018008330B1 BR112018008330B1 (pt) 2023-03-07

Family

ID=57460503

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018008330-5A BR112018008330B1 (pt) 2015-11-30 2016-11-30 Compostos 1,3,4-tiadiazol, composição farmacêutica compreendendo o mesmo e seu uso no tratamento de câncer

Country Status (28)

Country Link
US (1) US10040789B2 (pt)
EP (1) EP3383872B1 (pt)
JP (1) JP6821680B2 (pt)
KR (1) KR20180083411A (pt)
CN (1) CN108349965B (pt)
AR (1) AR106875A1 (pt)
AU (1) AU2016361834B2 (pt)
BR (1) BR112018008330B1 (pt)
CA (1) CA3005517C (pt)
CL (1) CL2018001409A1 (pt)
CO (1) CO2018006930A2 (pt)
DK (1) DK3383872T3 (pt)
DO (1) DOP2018000135A (pt)
EA (1) EA035519B9 (pt)
ES (1) ES2796562T3 (pt)
IL (1) IL259508A (pt)
MX (1) MX2018006483A (pt)
MY (1) MY195680A (pt)
NI (1) NI201800063A (pt)
NZ (1) NZ743699A (pt)
PE (1) PE20181522A1 (pt)
PH (1) PH12018501133A1 (pt)
SG (1) SG11201803808VA (pt)
SV (1) SV2018005700A (pt)
TN (1) TN2018000118A1 (pt)
TW (1) TW201731511A (pt)
WO (1) WO2017093301A1 (pt)
ZA (1) ZA201804361B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201520959D0 (en) 2015-11-27 2016-01-13 Astrazeneca Ab And Cancer Res Technology Ltd Bis-pyridazine compounds and their use in treating cancer
US9938265B2 (en) 2015-11-30 2018-04-10 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
TW201733587A (zh) 2015-11-30 2017-10-01 阿斯特捷利康公司 1,3,4-噻二唑化合物及其在治療癌症中之用途
ES2939506T3 (es) * 2018-10-16 2023-04-24 Medshine Discovery Inc Derivado de tiadiazol y usos del mismo como inhibidor de GLS1 para el tratamiento de cáncer
CN114560855B (zh) * 2021-03-26 2023-05-23 成都苑东生物制药股份有限公司 环烷基甲酰胺类衍生物、其制备方法及用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201607685SA (en) * 2011-11-21 2016-11-29 Calithera Biosciences Inc Heterocyclic inhibitors of glutaminase
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
WO2014079011A1 (en) * 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
EP3092235A2 (en) 2014-01-06 2016-11-16 Rhizen Pharmaceuticals S.A. Novel inhibitors of glutaminase
GB201409624D0 (en) * 2014-05-30 2014-07-16 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer

Also Published As

Publication number Publication date
CA3005517C (en) 2023-12-12
US20170333429A1 (en) 2017-11-23
TN2018000118A1 (en) 2019-10-04
NZ743699A (en) 2023-02-24
EA035519B1 (ru) 2020-06-29
JP6821680B2 (ja) 2021-01-27
AU2016361834B2 (en) 2019-11-14
ZA201804361B (en) 2019-07-31
JP2018535235A (ja) 2018-11-29
DK3383872T3 (da) 2020-06-08
PE20181522A1 (es) 2018-09-24
EA201891239A1 (ru) 2018-11-30
DOP2018000135A (es) 2018-06-30
WO2017093301A1 (en) 2017-06-08
BR112018008330B1 (pt) 2023-03-07
MX2018006483A (es) 2019-08-12
EA035519B9 (ru) 2020-08-10
EP3383872A1 (en) 2018-10-10
IL259508A (en) 2018-07-31
MY195680A (en) 2023-02-03
KR20180083411A (ko) 2018-07-20
AR106875A1 (es) 2018-02-28
TW201731511A (zh) 2017-09-16
US10040789B2 (en) 2018-08-07
CO2018006930A2 (es) 2018-10-10
EP3383872B1 (en) 2020-05-20
CA3005517A1 (en) 2017-06-08
NI201800063A (es) 2018-10-18
SG11201803808VA (en) 2018-06-28
CN108349965A (zh) 2018-07-31
CN108349965B (zh) 2021-10-26
PH12018501133A1 (en) 2019-01-21
ES2796562T3 (es) 2020-11-27
CL2018001409A1 (es) 2018-12-07
SV2018005700A (es) 2019-03-07
AU2016361834A1 (en) 2018-07-12

Similar Documents

Publication Publication Date Title
BR112018008330A2 (pt) compostos 1,3,4-tiadiazol e seu uso no tratamento de câncer
BR112022009557A2 (pt) Inibidores de kras g12c
BR112017028504A2 (pt) derivados de sulfamoilarilamida ciclizada e uso dos mesmos como medicamentos para o tratamento da hepatite b
PH12018500987A1 (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
MX2017000408A (es) Compuestos antiproliferativos y métodos de uso de los mismos.
BR112016015983A2 (pt) Compostos de indazol como inibidores de irak4, seus usos, e composição farmacêutica
BR112018007772A2 (pt) compostos de imidazo[4,5-c]quinolin-2-ona e seu uso no tratamento do câncer
AR092876A1 (es) Inhibidores no nucleosidos de la transcriptasa inversa
EA201692268A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
EA201692267A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
BR112018070536A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição
BR112020008258B8 (pt) Compostos de biarila substituída ou seus sais farmaceuticamente aceitáveis, sua composição e seu uso como inibidores de indoleamina 2,3-dioxigenase (ido)
PH12020552261A1 (en) Proteasome activity enhancing compounds
AR100694A1 (es) Compuestos de 1,3,4-tiadiazol y uso de los mismos para el tratamiento del cáncer
BR112018010806A2 (pt) compostos de 1,3,4-tiadiazol e uso dos mesmos no tratamento do câncer
EA201691566A1 (ru) Применение производных пиридазина для предупреждения или лечения атаксического синдрома
BR112018070514A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição
MX2021001612A (es) Compuestos utiles en terapia del vih.
MY187251A (en) [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases
CO2018006929A2 (es) "compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer"
EA202191588A1 (ru) Замещенные ксантиновые производные
BR112017021589A2 (pt) métodos para o tratamento de transtornos cardiovasculares
BR112018002681A2 (pt) ?composto, composição, e, método para tratamento de infecção por hiv?
BR112016020135A8 (pt) mistura de composto, seus usos, composição farmacêutica, e conjunto (kit)
BR112019014738A8 (pt) Composto, forma de dosagem sólida, composição farmacêutica, forma cristalina de composto, método para tratar infecção por hepatite c ou uma condição resultante de uma infecção por hepatite c, composto da fórmula, e, uso de um composto da fórmula

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/11/2016, OBSERVADAS AS CONDICOES LEGAIS